Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.

Trial Details

NCT ID
NCT04467723
Phase
PHASE1 / PHASE2
Sponsor
University of Kansas Medical Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Atezolizumab
Locations (sample)
  • Fairway, Kansas, United States|39.02223,-94.6319
  • Kansas City, Kansas, United States|39.11417,-94.62746

Key Eligibility Criteria

  • Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures
  • Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study
  • Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer
  • Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →